NCT07107139 is a NA clinical trial of Copenhagen group in Smokeless Tobacco, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT07107139?

NCT07107139 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT07107139?

Interventions in NCT07107139: Copenhagen group, Snus group.

What condition does NCT07107139 study?

NCT07107139 studies Smokeless Tobacco.

Is NCT07107139 still recruiting?

NCT07107139 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT07107139

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effects

Recruiting now NA Last updated 27 February 2026

What this trial tests

NA trial testing Copenhagen group in Smokeless Tobacco in 50 participants. Currently enrolling.

Timeline

30 March 2026

Primary endpoint
1 March 2027

1 March 2027

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	basic science
Enrollment	50
Start date	30 March 2026
Primary completion	1 March 2027
Estimated completion	1 March 2027
Sites	1 location across United States

Drugs / interventions tested

Copenhagen group
Snus group

Conditions studied

Smokeless Tobacco — all drugs for Smokeless Tobacco →

Sponsor

Roswell Park Cancer Institute

Who can join

21 and older, any sex, with Smokeless Tobacco. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study seeks to measure the effects of smokeless tobacco product risk messages on sensory experiences and future intentions to use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07107139 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07107139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing